21,000 Shares in Prestige Consumer Healthcare Inc. $PBH Purchased by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System purchased a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 21,000 shares of the company’s stock, valued at approximately $1,245,000.

Several other institutional investors also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA raised its holdings in shares of Prestige Consumer Healthcare by 10.2% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock valued at $40,147,000 after acquiring an additional 60,496 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of Prestige Consumer Healthcare by 547.4% in the fourth quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock worth $37,811,000 after acquiring an additional 520,186 shares during the last quarter. Leeward Investments LLC MA boosted its stake in shares of Prestige Consumer Healthcare by 23.3% in the fourth quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock worth $23,894,000 after acquiring an additional 73,162 shares during the last quarter. Legato Capital Management LLC increased its position in shares of Prestige Consumer Healthcare by 532.4% during the fourth quarter. Legato Capital Management LLC now owns 27,774 shares of the company’s stock worth $1,713,000 after purchasing an additional 23,382 shares in the last quarter. Finally, Brandes Investment Partners LP increased its position in shares of Prestige Consumer Healthcare by 93.2% during the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock worth $37,430,000 after purchasing an additional 292,744 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Trading Down 0.1%

Shares of Prestige Consumer Healthcare stock opened at $49.38 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. The stock’s 50 day simple moving average is $49.36 and its 200-day simple moving average is $58.27. The stock has a market cap of $2.34 billion, a P/E ratio of 12.63, a P/E/G ratio of 1.59 and a beta of 0.35. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $80.69.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The company had revenue of $281.62 million for the quarter, compared to analysts’ expectations of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business’s quarterly revenue was down 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Insider Activity

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at $2,354,671.80. This trade represents a 2.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.40% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).